• <input id="ycg2u"></input>
    <legend id="ycg2u"></legend>
    <strong id="ycg2u"><u id="ycg2u"></u></strong>
  • Enable Accessibility Enable Accessibility

    Press Releases and Position Statements


    Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan


    Joint Statement from Moderna and Takeda on the Investigation of Suspended Lots of Moderna’s COVID-19 Vaccine in Japan

    AUGUST 28

    Moderna and Takeda’s Response to the Incidents Announced by the Japanese Ministry of Health, Labour and Welfare (MHLW) associated with the Announced Suspension of Use of Specific Lots of Moderna’s COVID-19 Vaccine in Japan

    AUGUST 26

    Notice of Suspension of Use of Specific Lots of Moderna’s COVID-19 Vaccine in Japan (COVID-19 Vaccine Moderna Intramuscular Injection)

    JUNE 20

    Takeda Expands Moderna’s COVID-19 Vaccine Supply in Japan in Partnership with the Japanese Government

    MAY 21

    Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan

    MAY 10

    Takeda Announces Positive Interim Safety and Immunogenicity Data from its Phase 1/2 Study of Moderna’s COVID-19 Vaccine Candidate (TAK-919) in Japan

    APRIL 2

    CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

    MARCH 15

    Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine

    MARCH 5

    Takeda Submits New Drug Application to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan


    Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

    JANUARY 21

    Start of a Japanese Clinical Study of TAK-919, Moderna’s COVID-19 Vaccine Candidate


    COVID-19 and the Role of Diagnostic Testing for Asymptomatic and Pre-Symptomatic Individuals


    World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19

    OCTOBER 29

    Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan


    First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine


    19 Organizations from the Healthcare Community Unite to Form COVID-19 Testing Industry Consortium

    AUGUST 7

    Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

    AUGUST 3

    Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

    MAY 26

    Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

    MAY 7

    CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

    APRIL 6

    Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

    MARCH 25

    Takeda Research & Development and COVID-19

    MARCH 23

    Coronavirus and Product Supply

    MARCH 4

    Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19